Corcept Therapeutics (CORT): Notes From Management Meetings - Piper Jaffray

October 19, 2016 12:16 PM EDT
Get Alerts CORT Hot Sheet
Price: $7.47 -1.71%

Rating Summary:
    7 Buy, 3 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade CORT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on Corcept Therapeutics (NASDAQ: CORT) after hosting investor meetings with management.

The analyst also believes the platform is now entering a potentially transformative period for 2nd gen compounds to demonstrate clinical value in a broad range of cortisol-driven indications.

From ‘134, the analyst expects Phase II Cushing’s results during 2H17 to support efficacy without progesterone activity, opening the door to increased penetration of US (and EU).

In the next year, the analyst also anticipates progress from the ongoing oncology trials to confirm meaningful, replicable efficacy from mife’ (aka Korlym) and ‘134 in GR-expressing tumor types such as TNBC and CRPC. In advance of quarterly Korlym revenue performance, and this anticipated clinical and commercial progress for Corcept’s portfolio of cortisol-modulating compounds,

No change to the price target of $12.

For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.

Shares of Corcept Therapeutics closed at $6.50 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Management Comments

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment